ArriVent BioPharma said its Phase 3 FURVENT trial of firmonertinib missed its primary endpoint in previously untreated advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.
The higher 240 mg dose produced median progression-free survival of 11 months, versus 9.5 months for chemotherapy; the difference was not statistically significant (p=0.0654). The 160 mg dose recorded 8.4 months.
ArriVent shares plunged roughly 50–60% in trading after the results were announced, with reports varying by timing and market measure.
The company reported a trend toward improved overall survival, but those data are not yet mature. It said no new safety signals were identified and is assessing the full dataset and the drug’s future development path.
Sources:
ArriVent's Failed Trial Deals Blow to China-Origin Cancer Drug
ArriVent collapses on disappointing lung cancer data
ArriVent's cancer pill fails to 'meaningfully' delay disease ...
ArriVent FURVENT Phase 3 trial misses primary endpoint
ArriVent’s lung cancer drug trial misses primary endpoint By Investing.com
ArriVent stock tumbles 60% after trial misses primary endpoint By Investing.com
ArriVent says Phase 3 firmonertinib trial did not meet endpoint
US firm ArriVent's plunge shows risks facing China's biotech expansion into global markets
ArriVent BioPharma's Lung Cancer Drug Fails to Meet Primary Endpoint in Phase 3 Trial
ArriVent Announces Program Update from the Phase 3 FURVENT ...
ArriVent's lung cancer treatment fails late-stage trial
AVBP Plummets After Phase 3 Lung Cancer Trial Failure
Why ArriVent BioPharma (AVBP) Stock Is Down Today
ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low